These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19223380)

  • 1. Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature.
    Sidhu HK; Chaffee BH; Tvetenstrand CD; Sidhu JS
    Int J Surg Pathol; 2010 Oct; 18(5):384-7. PubMed ID: 19223380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Myers SA; Selim AA; McDaniel MA; Hall R; Zhang Y; Bartlett JA; True AL
    Antivir Ther; 2006; 11(7):935-9. PubMed ID: 17302257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.
    Ball RA; Kinchelow T;
    J Am Acad Dermatol; 2003 Nov; 49(5):826-31. PubMed ID: 14576660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication.
    Avelino-Silva VI; Li HY; Novaes CT
    AIDS Patient Care STDS; 2012 Feb; 26(2):71-2. PubMed ID: 22148866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enfuvirtide injection site reactions: a clinical and histopathological appraisal.
    Wallace BJ; Tan KB; Pett SL; Cooper DA; Kossard S; Whitfeld MJ
    Australas J Dermatol; 2011 Feb; 52(1):19-26. PubMed ID: 21332688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short communication safety, tolerability and pharmacokinetics of enfuvirtide administered by a needle-free injection system compared with subcutaneous injection.
    Gottlieb M; Thommes JA;
    Antivir Ther; 2008; 13(5):723-7. PubMed ID: 18771056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).
    Boyd MA; Truman M; Hales G; Anderson J; Dwyer DE; Carr A
    Antivir Ther; 2008; 13(3):449-53. PubMed ID: 18572758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.
    Hasson H; Biswas P; Galli L; Burastero SE; Danise A; Bigoloni A; Carini E; Locatelli M; Vecchi A; Lazzarin A; Castagna A
    New Microbiol; 2006 Oct; 29(4):223-30. PubMed ID: 17201088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fuzeon, first of the so-called "fusion inhibitor" drug in new class of AIDS treatments and its warnings].
    Hayashi T
    Nihon Rinsho; 2005 Jan; 63(1):173-82. PubMed ID: 15675339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized amyloidosis at the site of enfuvirtide injection.
    Morilla ME; Kocher J; Harmaty M
    Ann Intern Med; 2009 Oct; 151(7):515-6. PubMed ID: 19805777
    [No Abstract]   [Full Text] [Related]  

  • 14. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 16. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of therapy with a subcutaneously administered antiretroviral in treatment-experienced HIV-infected patients: understanding physician and patient perspectives.
    Horne R; Cooper V; Fisher M
    AIDS Care; 2008 Oct; 20(9):1029-38. PubMed ID: 18825512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fuzeon treatment forum, January 2004.
    Burgess GE
    Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.